| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1994PNAS...9110795S |
| P356 | DOI | 10.1073/PNAS.91.23.10795 |
| P932 | PMC publication ID | 45112 |
| P698 | PubMed publication ID | 7526379 |
| P5875 | ResearchGate publication ID | 15673486 |
| P50 | author | Jan Holmgren | Q5811529 |
| P2093 | author name string | Sun JB | |
| Czerkinsky C | |||
| P2860 | cites work | Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response | Q70591810 |
| Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen | Q70649982 | ||
| Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor | Q70745453 | ||
| Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines | Q72271829 | ||
| Orally induced tolerance. Definition at the cellular level | Q72636644 | ||
| Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin | Q72815583 | ||
| Effects of oral administration of type II collagen on rheumatoid arthritis | Q72936919 | ||
| Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development | Q33831194 | ||
| Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues | Q35093806 | ||
| An early component of delayed-type hypersensitivity mediated by T cells and mast cells | Q36347846 | ||
| Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding | Q36354467 | ||
| Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen | Q37401915 | ||
| Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin | Q37622936 | ||
| Could specific oral tolerance be a therapy for autoimmune disease? | Q37783108 | ||
| Actions of cholera toxin and the prevention and treatment of cholera | Q40310088 | ||
| Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems | Q40788029 | ||
| Inhibition of specific immune responses by feeding protein antigens. II. Effects of prior passive and active immunization | Q41633022 | ||
| Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen | Q41742673 | ||
| Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent | Q42935742 | ||
| Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen | Q44466252 | ||
| Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats | Q44815781 | ||
| Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein | Q46690191 | ||
| Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis | Q50127386 | ||
| Cellular dissemination of priming for a mucosal immune response to cholera toxin in rats | Q52223739 | ||
| Oral Rh treatment for severely immunised mothers | Q66702300 | ||
| Oral hyposensitization of children with pollinosis or house-dust asthma | Q67582219 | ||
| The induction of tolerance to a soluble protein antigen by oral administration | Q68928457 | ||
| Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments | Q69013296 | ||
| Influence of Repeated Administration of Antigen by the Oral Route on Specific Antibody-Producing Cells in the Mouse Spleen | Q69313330 | ||
| Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study | Q70478605 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholera | Q12090 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 10795-10799 | |
| P577 | publication date | 1994-11-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance | |
| P478 | volume | 91 |
| Q57075419 | A Pathogen-specific Epitope Inserted into Recombinant Secretory Immunoglobulin A Is Immunogenic by the Oral Route |
| Q36140954 | A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes |
| Q63370226 | A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection |
| Q45889680 | A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes |
| Q45877640 | A plant-based multicomponent vaccine protects mice from enteric diseases |
| Q93024677 | A review on edible vaccines and their prospects |
| Q35155875 | AB toxins: a paradigm switch from deadly to desirable |
| Q45884563 | An HIV-1 tat-autoantigen fusion protein suppresses insulitis in NOD mice |
| Q39658273 | Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model |
| Q46125947 | Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model |
| Q37667018 | Anti-diabetic effects of CTB-APSL fusion protein in type 2 diabetic mice |
| Q37001778 | Anti-inflammatory effect of cholera toxin B subunit in experimental stroke |
| Q33846429 | Antigen processing and presentation by intestinal epithelial cells - polarity and complexity |
| Q37869564 | Autoantigen based vaccines for type 1 diabetes. |
| Q34113929 | Autoantigens plus interleukin-10 suppress diabetes autoimmunity |
| Q34343280 | Bacteria-derived particles as adjuvants for non-replicating nasal vaccines |
| Q45889466 | Bacterial and plant enterotoxin B subunit-autoantigen fusion proteins suppress diabetes insulitis |
| Q34525958 | Bacterial toxins as tools for mucosal vaccination |
| Q64238423 | Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults |
| Q34045009 | Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis |
| Q38657465 | CBirTox is a selective antigen-specific agonist of the Treg-IgA-microbiota homeostatic pathway. |
| Q34972133 | Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins |
| Q34026162 | Cholera toxin - a foe & a friend. |
| Q39522002 | Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells |
| Q40976342 | Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity |
| Q36551840 | Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. |
| Q47913833 | Cholera toxin B suppresses allergic inflammation through induction of secretory IgA. |
| Q39741614 | Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development |
| Q41857594 | Cholera toxin induces a transient depletion of CD8+ intraepithelial lymphocytes in the rat small intestine as detected by microarray and immunohistochemistry |
| Q36367736 | Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression |
| Q24598726 | Cholera toxin: a paradigm of a multifunctional protein |
| Q90355622 | Consuming cholera toxin counteracts age-associated obesity |
| Q36544143 | Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit |
| Q48692006 | Delivery of Recombinant Tetanus–Superoxide Dismutase Proteins to Central Nervous System Neurons by Retrograde Axonal Transport |
| Q52025414 | Differential effect of cholera toxin on CD45RA+ and CD45RO+ T cells: specific inhibition of cytokine production but not proliferation of human naive T cells. |
| Q40976330 | Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance |
| Q74401546 | Efficacy of a food plant-based oral cholera toxin B subunit vaccine |
| Q46342747 | Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumulated in rice seed |
| Q34738751 | Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate |
| Q35482401 | Epitope maps of the Escherichia coli heat-labile toxin B subunit for development of a synthetic oral vaccine. |
| Q54150448 | Expression of cholera toxin B subunit oligomers in transgenic potato plants. |
| Q36990434 | Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts--oral administration protects against development of insulitis in non-obese diabetic mice |
| Q46682172 | Expression of cholera toxin subunits in plants |
| Q73507054 | Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies |
| Q34619696 | Gene therapy in diabetes |
| Q54544388 | Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo. |
| Q84081029 | Glutamic acid decarboxylase epitope protects against autoimmune diabetes through activation of Th2 immune response and induction of possible regulatory mechanism |
| Q33525565 | IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE) |
| Q37544969 | Identification and characterization of intestinal antigen-presenting cells involved in uptake and processing of a nontoxic recombinant chimeric mucosal immunogen based on cholera toxin using imaging flow cytometry |
| Q38971911 | Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease |
| Q34102006 | Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic |
| Q33546865 | Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic |
| Q34933032 | Immune response induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B subunit. |
| Q41759582 | Immune responses to dietary antigens: oral tolerance. |
| Q45220366 | Immunogenicity of a cholera toxin B subunit Porphyromonas gingivalis fimbrial antigen fusion protein expressed in E. coli |
| Q34993212 | Immunology and immunomodulation of corneal transplantation |
| Q34184898 | Immunomodulation using bacterial enterotoxins |
| Q36320323 | Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections |
| Q34307584 | Immunomodulators and delivery systems for vaccination by mucosal routes. |
| Q56556760 | Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice |
| Q81543203 | Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein |
| Q40949743 | Induction of tolerance in humans: effectiveness of oral and nasal immunization routes |
| Q34009585 | Intranasal immunization with recombinant Ascaris suum 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to A. suum infection in mice |
| Q35551202 | Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin |
| Q74586086 | Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid |
| Q44206781 | Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions |
| Q37069755 | Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. |
| Q34437669 | Mechanisms of vaccine adjuvanticity at mucosal surfaces. |
| Q73933686 | Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens |
| Q54542514 | Modulation of human monocytes by Escherichia coli heat-labile enterotoxin B-subunit; altered cytokine production and its functional consequences. |
| Q33776172 | Mucosal immunity and tolerance: relevance to vaccine development |
| Q39474002 | Murine models for mucosal tolerance in allergy |
| Q78402068 | Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice |
| Q74541097 | Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE) |
| Q40976422 | Neonatal oral tolerance |
| Q38229883 | Novel transgenic rice-based vaccines |
| Q35717195 | Oral Administration of Lactococcus lactis Expressing Synthetic Genes of Myelin Antigens in Decreasing Experimental Autoimmune Encephalomyelitis in Rats |
| Q28079063 | Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells |
| Q34624985 | Oral administration of a fusion protein between the cholera toxin B subunit and the 42-amino acid isoform of amyloid-β peptide produced in silkworm pupae protects against Alzheimer's disease in mice |
| Q43683297 | Oral administration of collagen conjugated with cholera toxin induces tolerance to type II collagen and suppresses chondritis in an animal model of autoimmune ear disease |
| Q36083396 | Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice |
| Q45953496 | Oral feeding of renal tubular antigen abrogates interstitial nephritis and renal failure in Brown Norway rats. |
| Q32154888 | Oral immunisation as a strategy for enhancing corneal allograft survival |
| Q40091210 | Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes |
| Q34707653 | Oral immunization with an attenuated Salmonella Gallinarum mutant as a fowl typhoid vaccine with a live adjuvant strain secreting the B subunit of Escherichia coli heat-labile enterotoxin |
| Q72834940 | Oral tolerance |
| Q77627766 | Oral tolerance and the treatment of rheumatoid arthritis |
| Q43544917 | Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres |
| Q73779689 | Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat. II. Adjuvant effects and bystander suppression in P2 peptide-induced EAN |
| Q79859166 | Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells |
| Q72296878 | Oral tolerance to haptens: intestinal epithelial cells from 2,4-dinitrochlorobenzene-fed mice inhibit hapten-specific T cell activation in vitro |
| Q41605290 | Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases |
| Q33683196 | Oral tolerance: mechanisms and therapeutic applications. |
| Q47346480 | Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease |
| Q54593721 | Oral-antigen delivery by way of a multiple emulsion system enhances oral tolerance. |
| Q73054337 | Oral-antigen delivery via a water-in-oil emulsion system modulates the balance of the Th1/Th2 type response in oral tolerance |
| Q73957921 | Overview of vaccines |
| Q24548763 | Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection |
| Q37351448 | Persistent suppression of type 1 diabetes by a multicomponent vaccine containing a cholera toxin B subunit-autoantigen fusion protein and complete Freund's adjuvant |
| Q50117900 | Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization |
| Q41030779 | Preserved epitope-specific T cell activation by recombinant Bet v 1-MBP fusion proteins. |
| Q73882350 | Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis |
| Q33597302 | Production of new/modified proteins in transgenic plants |
| Q33731344 | Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines |
| Q35101668 | Protection against autoimmune diabetes by silkworm-produced GFP-tagged CTB-insulin fusion protein. |
| Q73443851 | Purified cholera toxin B subunit from transgenic tobacco plants possesses authentic antigenicity |
| Q81593103 | Recent advances in immunotherapy of allergic rhinitis |
| Q36161912 | Refinement of polyclonal antibody production by combining oral immunization of chickens with harvest of antibodies from the egg yolk. |
| Q35482140 | Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit |
| Q33928456 | Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine |
| Q33577679 | Strategies of mucosal immunotherapy for allergic diseases |
| Q52681524 | Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. |
| Q44896920 | Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance |
| Q34629092 | Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. |
| Q42035404 | Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm |
| Q40173820 | Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses |
| Q43410357 | Synthesis and assembly of SIVmac Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato |
| Q44795390 | Synthesis and assembly of a cholera toxin B subunit-rotavirus VP7 fusion protein in transgenic potato |
| Q38334315 | Synthesis and assembly of anthrax lethal factor-cholera toxin B-subunit fusion protein in transgenic potato |
| Q40710316 | Synthesis of cholera toxin B subunit gene: cloning and expression of a functional 6XHis-tagged protein in Escherichia coli. |
| Q37628867 | The ABC of clinical and experimental adjuvants--a brief overview |
| Q37522842 | The B subunit of Escherichia coli heat-labile enterotoxin induces both caspase-dependent and -independent cell death pathways in CD8+ T cells |
| Q39233053 | The Role of Dendritic Cell Maturation in the Induction of Insulin-Dependent Diabetes Mellitus |
| Q73076852 | The influence of initial exposure timing to beta-lactoglobulin on oral tolerance induction |
| Q38482209 | The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice |
| Q47105986 | Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa |
| Q74102313 | Tolerance--will it end in tears? |
| Q37820669 | Towards a Chlamydia trachomatis vaccine: how close are we? |
| Q37494112 | Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit |
| Q57988037 | Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses |
Search more.